CervoMed (CRVO)
NASDAQ:CRVO
CRVO Stock Chart & Stats
$4.04
-$0.11(-4.76%)
At close: 4:00 PM EST
$4.04
-$0.11(-4.76%)
Day’s Range― - ―
52-Week Range$3.58 - $14.00
Previous CloseN/A
Volume72.82K
Average Volume (3M)112.80K
Market Cap
$37.41M
Enterprise Value$28.06M
Total Cash (Recent Filing)$20.86M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.17
Next Earnings
May 19, 2026EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding9,258,719
10 Day Avg. Volume143,994
30 Day Avg. Volume112,798
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)3.92
Price to Sales (P/S)17.83
P/FCF Ratio-3.05
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue86.99
Enterprise Value/Gross Profit86.99
Enterprise Value/Ebitda-1.00
Forecast
1Y Price Target
$20.80Price Target Upside414.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.35
Revenue Forecast (FY)$425.00K
Bulls Say, Bears Say
Bulls Say
Biomarker-driven Trial EnrichmentIdentification of a plasma biomarker to exclude Alzheimer’s co-pathology enables enrollment of patients most likely to respond, increasing the chance of a positive pivotal trial outcome.
Manufacturing And Intellectual PropertyA stable crystal formulation that permits a single crystallization step improves drug stability and scalability and could support novel patent claims to extend commercial exclusivity.
Regulatory PathwayFDA alignment on the primary endpoint, patient selection, trial size and duration provides a clear regulatory path for a single global randomized pivotal trial that could support an accelerated review if results are favorable.
Bears Say
Cash Runway And BurnAvailable cash appears limited relative to expected operating burn, increasing the likelihood of future fundraising that could dilute existing investors.
Financing DependencyAdvancing the pivotal trial depends on securing substantial additional financing, creating execution risk if capital cannot be raised on acceptable terms.
Widening LossesA widening net loss highlights ongoing cash consumption that may pressure development timelines and elevate the risk of funding-related delays.
CervoMed News
CRVO FAQ
What was CervoMed’s price range in the past 12 months?
CervoMed lowest stock price was $3.58 and its highest was $14.00 in the past 12 months.
What is CervoMed’s market cap?
CervoMed’s market cap is $37.41M.
When is CervoMed’s upcoming earnings report date?
CervoMed’s upcoming earnings report date is May 19, 2026 which is in 53 days.
How were CervoMed’s earnings last quarter?
CervoMed released its earnings results on Mar 17, 2026. The company reported -$0.88 earnings per share for the quarter, missing the consensus estimate of -$0.866 by -$0.014.
Is CervoMed overvalued?
According to Wall Street analysts CervoMed’s price is currently Undervalued.
Does CervoMed pay dividends?
CervoMed does not currently pay dividends.
What is CervoMed’s EPS estimate?
CervoMed’s EPS estimate is -0.79.
How many shares outstanding does CervoMed have?
CervoMed has 9,258,719 shares outstanding.
What happened to CervoMed’s price movement after its last earnings report?
CervoMed reported an EPS of -$0.88 in its last earnings report, missing expectations of -$0.866. Following the earnings report the stock price went up 5.104%.
Which hedge fund is a major shareholder of CervoMed?
Currently, no hedge funds are holding shares in CRVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CervoMed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.80 (414.85% Upside)
$20.80 (414.85% Upside)
Hedge Fund Trend
Decreased
By 74.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 13.3%
Last 30 Days ▲ 13.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-49.60%
12-Months-Change
Fundamentals
Return on Equity
-76.78%
Trailing 12-Months
Asset Growth
-37.38%
Trailing 12-Months
Company Description
CervoMed
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
CRVO Stock 12 Month Forecast
Average Price Target
$20.80
▲(414.85% Upside)
Technical Analysis
X4 Pharmaceuticals
―
ABVC BioPharma
―
Jasper Therapeutics
―
Prelude Therapeutics
―
Estrella Immunopharma
―
Ownership Overview
44.08% Insiders
4.16% Mutual Funds
10.03% Other Institutional Investors
38.08% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---